Abstract:
The prevalence of depression is about 2-3 times higher in diabetic patients compared to the general population, yet this comorbidity is poorly treated. This may partly be contributed to the inefficient pharmacotherapy. We evaluated if a novel 5HT3 receptor antagonist 4i (N-(3-Chloro-2-methylphenyl) quinoxalin-2-carboxamide), can prevent depression-like behavior associated with diabetes in mice. Also, the role of oxidative stress in antidepressant action of 4i was investigated.